Conference Coverage (AACR)

p53 Gene Therapy Downregulates Vascular Endothelial Growth Factor

Published in Gene Therapy Weekly, May 12th, 1997

Researchers explored the applicability of p53 gene replacement therapy as an antiangiogenic therapy for cancer.

Examinations of p53 have shown that it is a multifunctional molecule. Its functions include regulation of cell cycle, apoptosis, and angiogenesis as a transcriptional factor.

Masahiko Nishizaki, representing colleagues from the Okayama University Medical School, Japan, and the M.D. Anderson Cancer Center, Texas, presented data regarding the angiogenic factor of p53 gene therapy at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California.

"We analyzed 32 tumor samples...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-05-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry